

REPROCELL provides the services and materials needed to navigate the complex world of drug discovery and regenerative medicine

With scientists and laboratories on three continents, Reprocell has the scientific and clinical expertise to better translate clinical discoveries into therapies

Established in 2003 by preeminent Japanese university researchers, REPROCELL quickly became the leading stem cell research company in Japan. Reprocell has 2 business divisions:

Drug Discovery and Clinical Services

- Research Stem Cell Services
- Clinical Stem Cell Services
- Gene Editing Services
- Preclinical & Drug Discovery CRO
- Clinical Laboratory Services
- Human Tissue Samples
- Genomic Services
- Diagnostic Services

Products for Stem Cell Research and 3D Cell Culture

- Stem Cell Reagents
- Cells
- 3D Cell Culture
- Labware

Operates in 4 countries and employs over 100 scientist with stem cells and human tissue research expertise



Key Milestones

- 2003** Incorporation Of REPROCELL
- 2005** Started research reagent business
- 2007** iPS cell discovery by Dr Yamanaka (Kyoto University) Using REPROCELL's culture reprogramming factors
- 2009** Launched world's first iPS cell product -iPS derived cardiomyocytes (cells responsible for heart contractions)
- 2010** Launched world's first neurons derived from human iPS cells (dopaminergic neurons, motor neurons and cerebral nerves)
- 2012** Launched world's first hepatocytes derived from human iPS cells (basic structure of liver)
- 2013** Listed On JASDAQ
- 2014** Established Corporate VC with Shinsei Bank
- 2014** Acquired Reinnervate (UK), BioServe (USA) and Stemgent (USA)
- 2015** Acquired Biopta (UK)
- 2018** Acquired BioServe Biotechnologies India
- 2020** Stemchymal Stem cell regenerative medicine Clinical trial
- 2021** Started new coronavirus PCR testing business
- 2021** Started clinical iPS cell business
- 2022** Completed Stemchymal clinical trial

REPROCELL products have been cited in 6,000 papers to date

Tokyo Stock Exchange

Reprocell Inc
Growth Market / Chemicals
4978 (JP3974770004)
Listed on February 26, 2013

REPROCELL Leadership Team



Chikafumi Yokoyama, Ph.D
Chief Executive Officer

Dr Yokoyama joined Reprocell Inc. in 2004 as a General Manager of Business Development, a year after the formation of the company. Since 2005, he has been Chief Executive Officer during which time he raised investment funds, arranged the initial public offering, and managed several global corporate acquisitions. Prior to Reprocell, Dr Yokoyama worked as an R & D Leader for Sumitomo 3M, a subsidiary of 3M Corporation. And earlier, for nearly 8 years, he was employed in McKinsey and Company Inc. as a Management Consultant. Dr Yokoyama received his Ph.D in Chemistry from Tokyo University in 1996.

REPROCELL Inc.

MetLife Shin-yokohama Bldg. 9F, 3-8-11 Shin-yokohama, Kohoku-ku, Yokohama, Kanagawa 222-0033, Japan

REPROCELL USA Inc.

9000 Virginia Manor Road, Suite 207, Beltsville, 20705, USA

REPROCELL Europe Ltd.

- Services: Thomson Pavilion, Todd Campus, West of Scotland Science Park, Acre Road, Glasgow, G20 OXA, United Kingdom
- Products: NETPark Plexus, Thomas Wright Way, Sedgfield, Durham, TS21 3FD, United Kingdom

**Bioserve
Biotechnologies
(India) PVT Ltd.**

D4-D7, 1st Floor, Industrial Estate, Moula-Ali, Medchal-Malkajgiri Dist., Hyderabad-500040, Telangana, India